CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (NVIV) today reported financial results for the quarter ended September 30, 2015.
Mark Perrin, InVivo’s Chief Executive Officer and Chairman, said, “We continued to make substantive and fundamental progress at InVivo through the third quarter and communicated our advancements through several media, scientific, and medical outlets. We enrolled the last two patients of the planned five-patient pilot study and announced an AIS conversion in the third patient with a high thoracic injury at one month, which occurs less than four percent of the time.
Help employers find you! Check out all the jobs and post your resume.
